Overview

Phase Ⅱc Sutdy of Aolanti Weikang Tablets in FD PDS Patients

Status:
Unknown status
Trial end date:
2021-05-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and validity of Aolanti Weipang Tablets in Patients with Postprandial Discomfort Syndrome of Functional Dyspepsia
Phase:
Phase 2
Details
Lead Sponsor:
Jiangxi Qingfeng Pharmaceutical Co. Ltd.